TSE:ONC FY2024 EPS Estimate Cut by Cantor Fitzgerald

Oncolytics Biotech Inc. (TSE:ONC) – Analysts at Cantor Fitzgerald decreased their FY2024 earnings estimates for shares of Oncolytics Biotech in a report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will earn ($0.42) per share for the year, down from their previous estimate of ($0.36). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Trading Up 0.7 %

Shares of Oncolytics Biotech stock opened at C$1.39 on Monday. The company has a fifty day simple moving average of C$1.50 and a 200-day simple moving average of C$1.45. Oncolytics Biotech has a 12-month low of C$1.15 and a 12-month high of C$2.32. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The stock has a market cap of C$106.84 million, a price-to-earnings ratio of -3.63 and a beta of 1.35.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.